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CDK2 substrates <p>Engineered kinases and thiophosphate enrichment were used to identify many candidate CDK2 substrates in human cell lysates.</p>
Abstract
Background: Protein phosphorylation regulates a multitude of biological processes. However, the
large number of protein kinases and their substrates generates an enormously complex
phosphoproteome. The cyclin-dependent kinases - the CDKs - comprise a class of enzymes that
regulate cell cycle progression and play important roles in tumorigenesis. However, despite intense
study, only a limited number of mammalian CDK substrates are known. A comprehensive
understanding of CDK function requires the identification of their substrate network.
Results: We describe a simple and efficient approach to identify potential cyclin A-CDK2 targets
in complex cell lysates. Using a kinase engineering strategy combined with chemical enrichment and
mass spectrometry, we identified 180 potential cyclin A-CDK2 substrates and more than 200
phosphorylation sites. About 10% of these candidates function within pathways related to cell
division, and the vast majority are involved in other fundamental cellular processes. We have
validated several candidates as direct cyclin A-CDK2 substrates that are phosphorylated on the
same sites that we identified by mass spectrometry, and we also found that one novel substrate,
the ribosomal protein RL12, exhibits site-specific CDK2-dependent phosphorylation in vivo.
Conclusions: We used methods entailing engineered kinases and thiophosphate enrichment to
identify a large number of candidate CDK2 substrates in cell lysates. These results are consistent
with other recent proteomic studies, and suggest that CDKs regulate cell division via large
networks of cellular substrates. These methods are general and can be easily adapted to identify
direct substrates of many other protein kinases.
Background
Reversible protein phosphorylation is one of the most com-
mon posttranslational modifications and regulates virtually
all cellular processes. Protein kinases are among the largest
known gene families with more than 500 human kinase genes
that comprise nearly 2% of the open reading frames of the
human genome [1]. Moreover, approximately 30% of all cel-
lular proteins are phosphorylated [2]. The large number of
kinases and their substrates make it very difficult to deter-
mine which proteins are phosphorylated by specific kinases
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in vivo, but this information is critical to understanding
kinase functions and the control of biological processes in
general. Various strategies have been developed to identify
protein kinase substrates, and several have resulted from
recent technological advances in substrate detection.
Some approaches have utilized antibodies against phospho-
motifs within the substrate proteins as affinity reagents to
enrich for phosphorylated peptides. Examples include using
antibodies that recognize conserved motifs that are highly
specific to a particular kinase [3], as well as the use of phos-
phomotif antibodies combined with changes in physiological
conditions that stimulate kinase function [4]. However, it is
difficult to apply these approaches to kinases that phosphor-
ylate broader substrate motifs, since there is less epitope con-
servation among substrates. Another recent method
combined quantitative phosphoproteomics with kinase
knock-outs and cellular perturbations to identify kinase tar-
gets in yeast [5]. However, with these cell-based approaches,
it is often difficult to determine if the putative substrates are
direct kinase targets. An in vitro approach employing arrays
of proteins phosphorylated by isolated recombinant kinases
has been successfully used in a global analysis of yeast kinase
substrates, but this strategy may be difficult to apply to organ-
isms with larger proteomes [6].
A 'chemical genetic' approach developed by Kevan Shokat's
laboratory addresses many of these potential problems [7]. In
this technique, the kinase to be studied is mutated by replac-
ing a conserved bulky residue within the ATP-binding pocket
with a smaller residue. This creates an enlarged ATP binding
pocket that enables the mutant kinase to utilize bulky ATP
analogues that cannot be used by wild-type cellular kinases,
thereby isolating the activity of the mutant kinase from all
other cellular kinases [8]. This technique is broadly applica-
ble to most protein kinases and has led to important advances
in substrate identification, including the description of a large
number of potential cyclin-dependent kinase (CDK) sub-
strates in yeast [9-15]. However, several technical hurdles add
substantial challenges when applying this approach to mam-
malian kinases with broad substrate networks.
In this study, we report a method employing the Shokat strat-
egy to identify direct cyclin A-CDK2 substrates in human cell
lysates. CDK2 is activated by both the cyclin E and cyclin A
subunits, and cyclin A-CDK2 plays critical roles in cell cycle
control, primarily in G1 and S-phases [16,17]. We used an
engineered cyclin A-CDK2 and ATP-γ-S analogue to label pro-
teins with thiophosphates in cell lysates, and after digestion
of the protein mixtures, we employed a single-step chemical
enrichment procedure to selectively isolate thiophosphor-
ylated peptides. As these studies were nearing completion,
Blethrow  et al. [18] independently reported a similar
approach employing engineered CDK1 and thiophosphate
enrichment methods that they used to identify a group of 68
putative cyclin B-CDK1 substrates within Hela cell lysates.
We identified 180 proteins and over 220 phosphopeptides
that were phosphorylated in cell lysates by cyclin A-CDK2,
and these proteins represented diverse cellular pathways. To
validate these methods, we selected several candidate sub-
strates and confirmed that they were phosphorylated by cyc-
lin A-CDK2 in vitro on the same sites that we identified in the
screen. Finally, we selected one novel substrate, the ribos-
omal protein RL12, for further study: site-directed mutagen-
esis and phosphopeptide mapping confirmed that CDK2
phosphorylates RL12 in vitro and in vivo on the same site
determined by our methods.
Results and discussion
Utilization of ATP analogues by engineered CDKs
We generated mutant 'Shokat' CDKs containing amino acid
exchanges at a conserved bulky residue in their ATP binding
pockets. In the case of CDK2 and CDK3 this was a phenyla-
lanine to alanine exchange at position 80, designated CDK2
(F80A). We also synthesized 12 ATP analogues to determine
if the engineered CDKs can use these analogues to phosphor-
ylate recombinant Retinoblastoma (Rb) protein in vitro, and
found that they utilized N6-(2-phenylethyl)-ATP (PE-ATP)
most efficiently (Figure 1a, and data not shown). Although
both wild-type and cyclin E-CDK2 (F80A) used normal ATP
to phosphorylate glutathione-S-transferase (GST)-Rb pro-
tein, only the F80A kinase could use PE-ATP. Similar results
were obtained with cyclin E-CDK3, but in this case the F80A
mutant could no longer use normal ATP, although the struc-
tural basis for this observation is unclear (Figure 1a). These
studies confirmed that the wild-type and engineered kinases
exhibit the desired ATP specificities.
Whereas the mutant CDKs efficiently used PE-ATP to phos-
phorylate Rb in vitro, similar experiments utilizing radiola-
beled PE-ATP in cell lysates failed because the labeled
phosphate was cleaved from PE-ATP by an ATPase activity in
the lysates (data not shown). We therefore switched to the thi-
ophosphate form of the ATP analogue (PE-ATP-γ-S), which
was not hydrolyzed by lysates (Figure 1b). Although kinases
often use ATP-γ-S less efficiently than normal ATP, thiophos-
phorylation has several advantages in this context. First, thi-
ophosphates are more stable and resistant to phosphatases
[19]. Second, since there are no pre-existing thiophosphoryla-
tion events in the cells, thiophosphate labeling provides
unique markers for proteins phosphorylated by the mutant
kinase. Finally, the thiophosphate group has similar chemical
properties as the sulfhydryl group and is amenable to chemi-
cal modifications. We expressed and purified soluble wild-
type and cyclin A-CDK2 (F80A) complexes from bacteria and
carried out a similar Rb kinase assay to test their ability to use
PE-ATP-γ-S. As shown in Figure 1c, although both kinases
can use ATP or ATP-γ-S to phosphorylate GST-Rb protein (as
indicated by its electromobility shift) only the F80A mutant
can use PE-ATP-γ-S. We thus used PE-ATP-γ-S for all of our
subsequent studies.http://genomebiology.com/2008/9/10/R149 Genome Biology 2008,     Volume 9, Issue 10, Article R149       Chi et al. R149.3
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Single-step purification of thiophosphorylated peptides
The use of engineered CDKs and ATP analogues facilitates
highly specific substrate phosphorylation: the next challenge
is how to identify them within a complex lysate. We sought to
utilize the thiophosphate tags to covalently capture and
enrich thiophosphorylated peptides after phosphorylation
and digestion of the lysates. However, a key problem was to
chemically distinguish thiophosphopeptides and cysteine-
containing peptides. Although a chemoselective method for
enriching thiophosphopeptides has been described, the over-
whelming abundance of cysteine residues in a complex pro-
tein mixture makes this approach difficult [20]. We used a
simple capture-and-release method to selectively isolate thio-
phosphorylated peptides within trypsinized cell lysates (Fig-
ure 2a). Proteins within the lysate were phosphorylated in
vitro with cyclin A-CDK2 (F80A) and PE-ATP-γ-S. The pro-
tein mixture was subsequently digested and the resulting
peptides were mixed with Thiopropyl Sepharose 6B [21], an
activated disulfide resin that captures both cysteine-contain-
ing peptides and thiophosphopeptides through a disulfide
exchange reaction. Because traditional dithiothreitol (DTT)
elution releases both types of bound peptides, we utilized the
qualitative differences between resin-bound thiophosphate
peptides and cysteine-containing peptides at the phospho-
Characterization of the engineered CDKs Figure 1
Characterization of the engineered CDKs. (a) Cyclin E-CDK2/3 complexes, or their F80A engineered counterparts (indicated by asterisks), were 
immunoprecipitated from transfected U2OS cell lysates via the HA-tag on the CDK subunit and subjected to in vitro kinases assays with 10 μM of either 
normal ATP or PE-ATP analogue. Phosphorylation of GST-Rb was monitored by immunoblotting with a phosphospecific anti-pS780-Rb antibody (New 
England Biolabs). The wild-type kinases cannot use PE-ATP. (b) Thin-layer chromatography - analysis reveals hydrolysis of ATP in cell lysate and transfer 
to acceptor nucleotides (left). The positions of the free phosphate and ATP are indicated. In contrast, ATP-γ-S is not hydrolyzed in cell lysates (right). (c) 
Kinase assays were performed using wild-type and cyclin A-CDK2 (F80A) complexes purified from E. coli and GST-Rb in the presence of 200 μM of ATP, 
ATP-γ-S and PE-ATP-γ-S at room temperature for 2 h. Kinase reactions were analyzed by SDS gel electrophoresis and visualized by Coomassie staining. 
Extent of the GST-Rb phosphorylation was monitored by the electromobility shift of GST-Rb.
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rothiolatesulfide linkage and alkyldisulfide linkage, respec-
tively. At high pH values, the phosphorothiolatesulfide
linkage is hydrolyzed and the alkyldisulfide remains intact
[22]. Treatment of the resin with a strong base (such as
sodium hydroxide) specifically releases thiophosphopeptides
(and also converts them to normal phosphopeptides), but not
the cysteine-containing peptides, by hydrolyzing the phos-
phorothiolatesulfide linkage (Figure 2b). Because peptides
bound via cysteine are not eluted in the final step, we cannot
recover cysteine-containing thiophosphopeptides. Moreover,
the elution results in loss of the thiophosphate signature by
converting the thiophosphopeptide to a phosphopeptide. Our
thiophosphopeptide isolation method differs modestly from
that of Blethrow et al. [18] in that we capture the thiophos-
phopeptides using disulfide exchange chemistry (disulfide
resin) instead of alkylation (iodoacetamide resin), and we
selectively elute them with base hydrolysis rather than
oxidation.
To test the feasibility of this approach, we phosphorylated
GST-Rb with cyclin A-CDK2 (F80A) and PE-ATP-γ-S, and
applied our purification procedure to a trypsin digest of the
reaction mixture. The isolated peptides were analyzed by
electrospray tandem mass spectrometry (ESI-MS/MS) using
an ion trap mass spectrometer. Peptides were identified by
matching the tandem mass spectra to a human protein
sequence database (with GST-Rb sequence added) using
SEQUEST software [23]. The GST-Rb substrate contains five
cysteines as well as seven SP/TP sites, which are sites favored
for CDK phosphorylation [24]. We recovered multiple phos-
phopeptides containing only and all the expected phosphor-
ylation sites (Table 1). Furthermore, we recovered no
cysteine-containing peptides and very few non-specific pep-
Single-step purification of thiophosphopeptides Figure 2
Single-step purification of thiophosphopeptides. (a) General scheme for thiophosphospeptide isolation. Proteins were labeled with cyclin A-CDK2 (F80A) 
and PE-ATP-γ-S and subjected to tryptic digest. The resulting peptides were mixed with disulfide beads, which capture both thiophosphopeptides and 
cysteine-containing peptides. The beads were then treated with basic solution to selectively release only the phosphopeptides. (b) The chemistry 
underlying the thiophosphopeptide selectivity. Both thiophosphate and cysteine moieties contain reactive thiol groups that can be covalently captured by 
disulfide beads. At high pH values, the phosphorothiolatesulfide linkages (near the upper arrow) are hydrolyzed to allow the release of the bead-bound 
peptides while the alkyldisulfide linkages (near the lower arrow) are stable and thus peptides are retained on the beads. Note that during the hydrolysis of 
the phosphorothiolatesulfide linkage, thiophosphate is converted to normal phosphate.
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tides. This provided a proof-of-principle for our large-scale
assays.
Identification of human cyclin A-CDK2 substrates in 
cell lysates
Our goal was to identify potential cyclin A-CDK2 substrates
on a proteome-wide scale. To reduce the sample complexity,
we fractionated the whole cell lysate of HEK293 cells into 11
fractions using ion-exchange chromatography and ammo-
nium sulfate precipitation (Additional data file 1). We then
carried out in vitro kinase assays on each fraction. As a posi-
tive control, we also added a small amount of GST-Rb to each
reaction. After digesting the reaction mixture with trypsin, we
applied our purification protocol to isolate the thiophos-
phopeptides from the peptide mixtures. The recovered pep-
tides were subjected to liquid chromatography-MS/MS
analysis and database searching. We recovered varying num-
bers of peptides and at least one Rb phosphopeptide from
each of the lysate fractions (Additional data file 2).
CDKs phosphorylate proteins in a proline-directed manner
on either serine or threonine, and numerous studies support
the idea that the motif S/T-P-X-R/K represents the CDK con-
sensus motif. From the phosphopeptides we identified a total
of 203 proteins: 180 candidates were phosphorylated within
S P  o r  T P  m o t i f s  ( p r o l i n e - d i r e c ted; Additional data file 3).
These candidate substrates represent a wide range of biologi-
cal processes, including cell cycle control, DNA and RNA
metabolism, translation and cellular structures (Figure 3). A
total of 96 out of 222 (43%) of the proline-directed sites con-
formed to the known CDK consensus (with a positively
charged residue in the +3 position). Interestingly, about 24%
of the proline-directed sites (53/222) contained a positively
charged residue in either the +4 or +5 positions, suggesting
that this motif may also be favored by CDK2. Indeed, Ble-
throw et al. [18] also noted that a substantial number of cyclin
B-CDK1 substrates contain non-consensus sites. For the pep-
tides that contained non-consensus sites, we found that about
50% of the corresponding proteins carried at least one K/
RXLφ or K/RXLXφ motif (where φ is a large hydrophobic res-
idue and X is any amino acid) distal to the phosphorylation
sites, and almost all of them carried at least one minimal RXL
motif (Additional data file 3). This is consistent with the well-
established idea that these motifs promote cyclin A-CDK2
binding to substrates [16]. In addition to selecting for phos-
phorylations with CDK consensus motifs, we identified 28
proteins that have been previously implicated as CDK sub-
strates (marked in bold in Additional data file 3) [25-52].
T h u s ,  n e a r l y  1 5 %  o f  o u r  c a n d i d a t e s  h a v e  b e e n  p r e v i o u s l y
found as CDK targets, further supporting the idea that our
methods captured and enriched for CDK2 substrates. Finally,
43% of the phosphorylations we found have been previously
identified in large-scale, in vivo phosphoproteome analyses,
indicating that these phosphorylations are not limited to our
in lysate conditions [53-58].
Both our studies and those reported by Blethrow et al. [18]
used similar phosphopeptide isolation schemes and related
cyclin-CDKs, and we anticipated that there might be substan-
tial overlap in the substrates revealed by both studies. Indeed,
we found nearly 50% (30/68) of the cyclin B-CDK1 substrates
in our list of cyclin A-CDK2 candidates; thus, these methods
are robust and reproducible (Additional data file 4). How-
ever, there are also substantial differences between the two
lists, and these likely resulted from many factors, including
procedural differences, different cell types, incomplete pep-
tide identification by MS, and substrate specificity conferred
by the cyclin and/or kinase subunits. Some of these differ-
ences may also reflect the different biological functions of cyc-
lin A-CDK2 and cyclin B-CDK1. For example, we found nine
proteins involved in protein translation and/or ribosome
function, but none of these proteins were found with cyclin B-
CDK1, despite their relatively high abundance.
Although we identified a number of known CDK2 substrates,
we did not identify some previously described CDK2 sub-
strates. Some of the factors listed above may also account for
the failure to find known CDK2 substrates in our analyses. In
addition, substrates already phosphorylated by endogenous
CDKs would not have been thiophosphorylated in vitro. It is
also possible that some proteins were not solubilized during
lysate preparation and/or the sonication step and excluded
from our analyses. Finally, it is possible that large protein
complexes may have been disrupted by the fractionation pro-
cedures prior to the kinase reaction, and that proteins that are
phosphorylated by CDK2 only in the context of these com-
plexes may not be discovered by our methods.
We also recovered four phosphopeptides corresponding to
cyclin A and CDK2 and 27 additional phosphopeptides with
Table 1
Phosphopeptides identified from in vitro phosphorylated GST-Rb
Peptide sequence SP/TP sites
R.GSTRPPTLS*PIPHIPR.S† S780
R.GSTRPPTLSPIPHIPRS*PYK.F† S788
R.SPYKFPSS*PLR.I S795
R.IPGGNIYIS*PLKSPYK.I S807
R.IPGGNIYISPLKS*PYK.I S811
R.IPGGNIYIS*PLKS*PYK.I S807, S811
K.ISEGLPT*PTK.M T821
K.ISEGLPT*PTKMTPR.S T821
K.ISEGLPTPTKMT*PR.S T826
K.ISEGLPT*PTKMT*PR.S T821, T826
Phosphorylation sites identified with highest probability are marked by 
boldfaced letters and asterisks to their right. The other boldfaced 
serine(s) and threonine(s) within the same peptide are potential 
alternative phosphorylation sites for the ones marked with the asterisk 
due to the ambiguity in assigning the exact site(s) of phosphorylation. 
†These are unnatural peptides containing partial sequences of Rb 
protein and GST fusion.http://genomebiology.com/2008/9/10/R149 Genome Biology 2008,     Volume 9, Issue 10, Article R149       Chi et al. R149.6
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non-proline directed sites (Additional data file 5). We sus-
pected these phosphopeptides resulted from auto-phosphor-
ylation of cyclin A-CDK2 and background phosphorylation by
other kinases, and others have reported similar background
phosphorylation [15]. To test these possibilities, we carried
out a control kinase reaction using cyclin A-CDK2 (F80A) and
PE-ATP-γ-S with no cell lysate added and recovered three of
the four cyclin A-CDK2 peptides (Additional data file 5). Fur-
thermore, when we performed a similar 'kinase-only' reaction
in the presence of γ-32P-ATP, we observed 32P incorporation
into both of these proteins in a dose-dependent manner
(Additional data file 6). These experiments confirmed that
there was background auto-phosphorylation of cyclin A-
CDK2 in the original assays.
We also performed control kinase reactions using the lysate
fractions, GST-Rb 'spike-in', and PE-ATP-γ-S without the
addition of cyclin A-CDK2. These 'no-kinase' control reac-
tions phosphorylated 7 of the 27 non-proline directed phos-
phopeptides on our list (Additional data file 5), suggesting
that most, if not all, of these phosphopeptides resulted from
background phosphorylation by kinases that are able to use
the ATP analogue to a limited extent. For example, most of
these peptides contain acidic residue-directed phosphoryla-
tion sites that are casein kinase 2 motifs. Casein kinase 2 is
unique in that it can utilize GTP as well as ATP; thus, the
active site may accommodate the bulky ATP analogues, such
as PE-ATP [59]. Importantly, we did not recover any Rb phos-
phopeptides from these control experiments, indicating that
there was no non-specific CDK activity in our assays. We also
recovered 44 unmodified peptides, 12 of which contained
cysteine residues. The majority of these peptides originated
from several lysate fractions (Additional data file 2). We sus-
pect these resulted from low-level non-specific binding of
peptides to the resin despite stringent wash conditions, and in
the case of the cysteine-containing peptides, from a small
amount of hydrolysis of the alkyldisulfide linkage during the
elution step. In summary, our methods were highly selective,
and our studies identified a surprisingly large group of candi-
date cyclin A-CDK2 substrates, most of which have not been
previously identified as CDK targets.
Validation of candidate substrates as cyclin A-CDK2 
targets
We employed several strategies to validate some of the novel
candidates in our list as cyclin A-CDK2 substrates. Because
our protein identifications were based on peptide sequences,
we began by confirming that cyclin A-CDK2 phosphorylated
three full-length and native candidates that were immuno-
precipitated via epitope tags from transfected 293 cells (EF2,
TRF2, and RAP1). Because these proteins were not present on
the cyclin B-CDK1 list [18], we determined if they are also
phosphorylated by cyclin B-CDK1. Each CDK2 candidate was
phosphorylated by both cyclin A-CDK2 and cyclin B-CDK1,
although EF2 was phosphorylated to a lesser extent than
either TRF2 or RAP1 (Figure 4a). We also expressed TRF2,
RAP1, and the ribosomal protein RL12 as GST-fusions and
purified them from Escherichia coli. When we used cyclin A-
CDK2 to phosphorylate TRF2 and RAP1 in vitro, the proteins
were highly phosphorylated, and MS analyses revealed that
these phosphorylations occurred on the same sites we initially
identified (Figure 4b). We also used cyclin A-CDK2 and cyclin
B-CDK1 to phosphorylate GST-RL12, and found that both
CDKs also phosphorylated RL12 in vitro (Figure 4c). These
Classification of proteins by functional category Figure 3
Classification of proteins by functional category. Numbers indicate identified proteins in each category.
Chromatin packaging and 
remodeling (12)
DNA replication,
recombination, and repair
(8)
Uncharacterized (35) Cell cycle (14)
mRNA transcription,
processing, and
regulation (44)
Cellular structure,
organization and
trafficking (35)
Signal transduction (3)
Protein phosphorylation
and ubiquitination (5)
rRNA and tRNA 
metabolism (6)
Biosynthesis and general 
metabolism (9)
Ribosomes and 
translational regulation (9)http://genomebiology.com/2008/9/10/R149 Genome Biology 2008,     Volume 9, Issue 10, Article R149       Chi et al. R149.7
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studies thus confirm that the peptides identified in our screen
represent proteins that can be phosphorylated by cyclin A-
CDK2, at least in vitro. Although we did find qualitative dif-
ferences in the ability of cyclin A-CDK2 and cyclin B-CDK1 to
phosphorylate specific proteins, in each case the candidates
were phosphorylated by both CDKs. Because the enzyme
preparation we used in these studies contained an excess of
free CDK2 (F80A), we considered the possibility that some
substrate phosphorylations might result from the association
of endogenous cyclins with CDK2 (F80A) that was either
monomeric, or that may have dissociated from cyclin A dur-
ing the assay conditions. We found that the amount of cyclin
B-CDK2 (F80A) activity in these extracts was negligible com-
pared with cyclin A-CDK2 (F80A), and we could not detect
Figure 4
In vitro validation of selective candidate CDK2 substrates. (a) HEK293 cells were transiently transfected with vectors expressing FLAG-tagged EF2, TRF2, 
and RAP1. Anti-FLAG antibody immunoprecipitates were in vitro phosphorylated with cyclin A-CDK2 or cyclin B-CDK1 in the presence of γ-32P-ATP 
(upper left panels). In parallel reactions, histone H1 was phosphorylated as a control to normalize the activities of cyclin A-CDK2 and cyclin B-CDK1 (right 
panel). 'C' denotes 'kinase only' reactions without transfected substrates (left panel) and 'no kinase' reaction (right panel). Protein samples were separated 
by SDS PAGE and the gels were transferred onto PVDF membranes. Phospho-signals were visualized by autoradiography. The membrane was 
subsequently probed with anti-FLAG antibody (Sigma-Aldrich) to confirm the identity of the phospho-signal bearing band (lower left panels). The asterisk 
represents a non-specific band from the commercial cyclin B-CDK2 preparation. (b) Kinase reaction was carried out using γ-32P-ATP, and GST-TRF2, 
GST-RAP1, GST-Rb (positive control) and GST (negative control) as substrates in the presence or absence of wild-type cyclin A-CDK2 kinase. Reactions 
were visualized by SDS PAGE followed by Coomassie staining and autoradiography (left panel). A similar kinase assay was carried out using wild-type cyclin 
A/CDK2 and ATP-γ-S, and subsequently subjected to a phosphopeptide isolation scheme. MS analysis confirmed that TRF2 and RAP1 were each 
phosphorylated on the exact sites we identified from the screen with one additional site for RAP1 (right panel). (c) Kinase assay was carried out using γ-
32P-ATP, cyclin A-CDK2 or cyclin B-CDK1 with increasing amounts of purified GST-RL12. Samples were separated by SDS PAGE and the gel was stained 
with Coomassie (lower panel) followed by autoradiography (upper panel). 'C' denotes 'kinase only' reactions without transfected substrates.
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any cyclin E-CDK2 (F80A) activity (Additional data file 7).
Nonetheless, we cannot exclude the possibility that some pep-
tides may have been phosphorylated by CDK2 (F80A) in com-
plex with an endogenous cyclin, and the specificity of any
candidate substrate for cyclin A versus other cyclins that acti-
vate CDK2 needs to be validated as described below.
Validation of RL12 as an in vivo CDK2 substrate
The above studies validated several novel candidates identi-
fied in our screen as CDK2 substrates in vitro. However, to
determine if a novel substrate is also phosphorylated by
CDK2 in vivo, we performed a more comprehensive analysis
of the ribosomal protein RL12. We first mixed immunopre-
cipitates of epitope-tagged cyclin A-CDK2 and RL12
expressed in human cells in the presence of γ-32P-ATP and
found that cyclin A-CDK2 phosphorylated RL12 in vitro (Fig-
ure 5a). The phosphorylation was largely abolished in a
mutant RL12 where the identified phosphoserine S38 was
replaced with an alanine, and it was restored when S38 was
replaced with a threonine (Figure 5b). We then used phos-
phopeptide mapping to identify the peptide containing S38,
and confirmed that it was directly phosphorylated by CDK2 in
vitro (Figure 5c). To test if RL12 is also phosphorylated in
vivo in a CDK2-dependent manner at the same site, we met-
abolically labeled cells with 32P-orthophosphate, and immu-
noprecipitated wild-type or RL12-S38A from cells
overexpressing either cyclin E-CDK2, catalytically inactive
cyclin E-CDK2, or the CDK inhibitor p21 (to inhibit endog-
enous CDKs) [60]. Because we cannot study endogenous
RL12 phosphorylation due to the lack of a suitable anti-RL12
antibody, these studies examined the phosphorylation of
ectopic RL12 in vivo (these transfection conditions led to an
approximately five- to ten-fold overexpression of RL12
mRNA (Additional data file 8). We found that wild-type RL12,
but not RL12-S38A, was phosphorylated in vivo (Figure 5d).
This phosphorylation was enhanced in cells overexpressing
cyclin E-CDK2, but not inactive cyclin E-CDK2, and was
diminished in cells overexpressing the p21 CDK inhibitor
(which inhibits endogenous cyclin-CDKs; Figure 5d). Finally,
we used phosphopeptide mapping and phosphoamino acid
analyses of RL12 protein immunoprecipitated from the
labeled cells and confirmed that RL12 phosphorylation by
cyclin E-CDK2 in vivo also occurred on S38 (Figure 5e). RL12
S38 phosphorylation in vivo has also been reported in phos-
phoproteome studies [54,55].
Although we have validated each of the novel candidates that
we have tested thus far by showing that the full-length pro-
teins are phosphorylated by CDK2, some candidates on our
list will likely prove not to be physiologically relevant cyclin
A-CDK2 substrates. For example, the kinase reactions were
performed in lysates, and in vivo subcellular compartmental-
ization may restrict the access of CDK2 to some candidates.
Moreover, it is possible that other cellular kinases are either
redundant with, or more important than, CDK2 with respect
to individual substrates in vivo. It is thus critical that candi-
dates be rigorously evaluated in as physiological a context as
possible. Towards this end, in ongoing studies we are using a
gene targeting approach to mutate a subset of these phospho-
rylation sites in the endogenous genes to study their physio-
logical significance.
Conclusions
In summary, we describe a rapid and efficient method to
identify candidate CDK substrates in cell lysates. We identi-
fied 180 candidate cyclin A-CDK2 substrates and found that
our method is robust, sensitive, and capable of identifying
novel CDK2 targets. Since most protein kinases have con-
served ATP binding domains and the kinetics of thiophospho-
rylation can be optimized [61], these methods should be
broadly applicable to the study of many kinases and their sub-
strate networks. Moreover, thiophosphorylation-based phos-
phopeptide isolation should also facilitate the mapping of
phosphorylation sites within individual proteins or protein
complexes in vitro.
Materials and methods
Reagents, cell culture, recombinant protein expression 
and purification
All standard chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Triphosphate synthesis was carried out
according the method of Ludwig [62]. PE-ATP was synthe-
sized similar to as previously described [63] with N6-(2-phe-
nylethyl)-adenosine as a precursor. PE-ATP-γ-S was custom
synthesized by TriLink Biotechnologies (San Diego, CA,
USA). All CDK (CDK2 (F80A) and CDK3 (F80A)) and RL12
phosphosite mutants were generated by site-directed muta-
genesis with the Quick Change method (Stratagene, La Jolla,
CA, USA). All cDNAs used in this study except TRF2 and
RAP1 were generated from human mRNA via RT-PCR, and
clones were sequenced. RAP1 cDNA was purchased from
Open Biosystems (Huntsville, AL, USA). A TRF2 clone was
obtained from Addgene (Addgene plasmid 16066, Cam-
bridge, MA, USA). U2OS and HEK293 cell lines were main-
tained in Dulbecco's modified Eagle's medium with 10% fetal
calf serum and expression of wild-type and mutant CDKs and
other proteins in U2OS cells were performed by transient
transfections or co-transfections via calcium phosphate pre-
cipitation using standard procedures. CDKs expressed in
human cells were purified by immunoprecipitation using
12CA5 antibody for HA-tagged Cdk subunits or using anti-
bodies against the cyclin subunit. GST-Rb (GST fused to the
carboxy-terminal 156 amino acids of Rb), GST-RL12, GST-
TRF2, and GST-RAP1 were expressed in bacteria and purified
using standard glutathione resin. Purified cyclin A-CDK2 and
cyclin B-CDK1 kinases used in Figure 4 were purchased from
New England Biolabs (Beverly, MA, USA).http://genomebiology.com/2008/9/10/R149 Genome Biology 2008,     Volume 9, Issue 10, Article R149       Chi et al. R149.9
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Preparation of cyclin A-CDK2 complexes expressed in 
bacteria
Active and soluble wild-type and F80A cyclin A-CDK2 com-
plexes were produced by co-expressing Saccharomyces cere-
visiae GST-CAK1, full-length untagged cyclin A and His6-
tagged CDK2 in bacteria similar to the commercial version
(New England Biolabs). Cyclin A and His6-CDK2 were cloned
into the pRSFDuet-1 vector (Novagen, San Diego, CA, USA)
and GST-CAK1 was cloned into pGEX-2T vector (GE Health-
care, Piscataway, NJ, USA). All three proteins were co-
expressed by transforming an E. coli BL21 strain with both
plasmids. For large scale preparation, cells expressing F80A
cyclin A-CDK2 were grown in 500 ml of LB medium to OD600
of 0.8 and isopropyl β-D-thiogalactoside (IPTG) was added to
Phosphorylation of RL12 in vitro and in vivo Figure 5
Phosphorylation of RL12 in vitro and in vivo. (a) HA-tagged RL12 or vector control ('vec') were transiently transfected into U2OS cells and 
immunoprecipitated using 12CA5 antibody. Cyclin A-CDK2 complexes were also transiently expressed separately in U2OS cells and immunoprecipitated 
using an antibody against cyclin A. Kinase assays were carried out using the RL12 (or control) immunoprecipitate with or without the cyclin A-CDK2 
immunoprecipitate in the presence of γ-32P-ATP. (b) Similar assays were conducted using cyclin A-CDK2 and RL12 immunoprecipitates containing wild-
type (wt) and the indicated RL12 phosphosite mutants. The asterisk denotes the light chain of the antibody. (c) Phosphopeptide mapping and 
phosphoamino acid analysis of the radiolabeled wild-type (left panel) and S38T mutant (right panel) of RL12. (d) Wild-type RL12, RL12-S38A, or vector 
control was transiently co-transfected with cyclin E-CDK2, catalytically inactive (dn) cyclin E-CDK2, or p21. All cells were subjected to 32P 
orthophosphate labeling. RL12 was immunoprecipitated from cell lysates and visualized by SDS PAGE followed by autoradiography. (e) Phosphopeptide 
mapping analysis was also carried out on the radiolabeled RL12 shown in (d). The bottom arrow shows a second and minor phosphorylation site detected 
in vivo.
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0.5 mM. Cells were then cultured overnight at 37°C before
being harvested by centrifugation. The cell pellet was lysed by
incubating with 20 ml lysis buffer (50 mM Tris, pH 7.5, 1 mM
DTT, 1 mM MgCl2, 25 U/ml Benzonase (Novagen), 2 mg/ml
lysozyme (Sigma-Aldrich) and protease inhibitors cocktail
(Sigma-Aldrich)) at room temperature for 1 h. After NaCl was
added to 250 mM and Triton X-100 to 0.025%, the cell slurry
was sonicated followed by centrifugation. The supernatant
was dialyzed against phosphate-buffered saline (PBS) before
incubation with 3 ml of Ni-NTA resin (Qiagen, Valencia, CA,
USA), which was washed sequentially with 15 ml PBS and low
imidazole buffer (30 mM Tris, pH 7.5, 150 mM NaCl, 50 mM
imidazole), and eluted with 6 ml high imidazole buffer (30
mM Tris, pH 7.5, 150 mM NaCl, 300 mM imidazole).
Immunoblotting, immunoprecipitation, 
orthophosphate labeling, and phosphoamino acid 
analysis
These procedures were described previously [64].
Preparation and fractionation of 293 native cell lysates
HEK293 cells were grown on 15 cm plates to near confluency
and harvested in PBS buffer. Cell pellets were resuspended in
hypotonic lysis buffer (50 mM Tris, pH 7.5, 1 mM DTT, 1 mM
MgCl2, 0.1% Triton X-100, 25 U/ml Benzonase (Novagen),
and protease inhibitors cocktail (Sigma-Aldrich)) and incu-
bated at 4°C, followed by sonication in 150 mM NaCl. Cell
debris was pelleted by centrifugation and the supernatant was
diluted such that the salt concentration was below 25 mM.
The whole cell lysate was then loaded onto a SP Sepharose
(GE Healthcare) column manually by atmospheric pressure
and the flowthrough was collected. After washing the column
with loading buffer (30 mM Tris, pH 7.5, 25 mM NaCl, 1 mM
DTT), bound proteins were eluted sequentially with load
buffer containing 100 mM, 200 mM, 300 mM, 400 mM, and
600 mM NaCl. The flowthrough was loaded onto a Q Sepha-
rose (GE Healthcare) column and similar procedures were
carried out to collect flowthrough and elute the column. Pro-
teins from Q Sepharose flowthrough were pelleted by ammo-
nium sulfate precipitation at 60% and resuspended in load
buffer. All fractions were concentrated with salt concentra-
tion adjusted between 100 and 200 mM by serial dilution and
concentration. These fractions were used in the first set of
experiments and subsequently dialyzed extensively against a
Tris buffer (30 mM Tris, pH 7.5, 150 mM NaCl) to be used in
a second set of experiments.
In vitro kinase assays and purification of 
thiophosphorylated peptides
Kinase assays using kinases purified from human cells have
been described previously [64]. For kinase assays using cell
lysate fractions (or GST-Rb) and PE-ATP-γ-S, recombinant
wild-type and F80A cyclin A-CDK2 complexes purified from
E. coli (as described above) were used. In each of the lysate
reactions, about 100-200 μg of lysate fraction (and 100-200
ng of GST-Rb as positive control) was mixed with approxi-
mately 1-2 μg of cyclin A-CDK2 (F80A) complex, 250 mM PE-
ATP-γ-S in kinase reaction buffer (40 mM Tris, pH 7.5, 10
mM MgCl2, 50 mM NaCl). The reaction was incubated at
30°C for 5 h and the protein mixture was denatured by adding
acetonitrile to 15% and digested with trypsin (1/20 mass
ratio) at 37°C for at least 6 h. Peptides were then incubated
with 20 μl of disulfide beads Thiopropyl Sepharose 6B (GE
Healthcare) with rotation at room temperature overnight.
The beads were loaded onto a Micro Bio-Spin column (Bio-
Rad Laboratories, Hercules, CA, USA), and washed sequen-
tially with 3 ml water, 5 ml of 30% acetonitrile in 0.1% formic
acid, 5 ml of 2 M NaCl, and 3 ml water. Beads were collected
and incubated with 20 μl of 20 mM NaOH at room tempera-
ture for 2 h. The eluate was neutralized and acidified with 1%
formic acid to pH 3 for direct analysis. Similar phosphopep-
tide capturing protocol was carried out for the GST-Rb kinase
assay using 5 μg of GST-Rb and 0.5 μg of cyclin A-CDK2
(F80A) complex.
Mass spectrometry analysis and database search
Phosphopeptides samples were analyzed by microcapillary
high performance liquid chromatography-electrospray ioni-
zation-MS/MS using an ion-trap mass spectrometer (LCQ,
ThermoFinnigan, San Jose, CA, USA). Peptides were pres-
sure-loaded onto a 75 μM × 12 cm self-packed C18 column
and resolved by a non-linear gradient of 5-28% acetonitrile
containing 0.1% formic acid at the flow rate of 200 nl/minute
over the course of 2 h. Tandem spectra acquired were
searched against the human NCI database (07.20.2006)
using SEQUEST. Search parameters included one tryptic end
and differential mass modification to serine and threonine
due to phosphorylation. For listing purposes, all entries were
manually updated using current Swiss-Prot nomenclature.
Search results from two independent experiments on each
lysate fraction were pooled and filtered using the statistical
tool PeptideProphet [65]. Peptides with probabilities higher
than 0.9 (error rate <1.8%) were manually validated to fur-
ther exclude ones with poor MS/MS spectra before inclusion
in the final list.
Abbreviations
CDK, cyclin-dependent kinase; DTT, dithiothreitol; GST, glu-
tathione-S-transferase; MS, mass spectrometry; MS/MS,
tandem MS; PBS, phosphate-buffered saline; PE-ATP, N6-(2-
phenylethyl)-ATP; Rb, Retinoblastoma.
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Additional data files
The following additional data are available. Additional data
file 1 is a figure showing the scheme of HEK293 cell lysate
fractionation. Additional data file 2 is a table listing the num-
bers of peptides identified in the lysate fractions. Additional
data file 3 is a table listing the identified proline-directed
phosphopeptide sequences, the corresponding protein
names, and their functional categorizations. Additional data
file 4 is a table comparing the proteins and phosphopeptides
identified for cyclin A-CDK2 and cyclin B-CDK1. Additional
data file 5 is a table listing the phosphopeptides with non-pro-
line-directed sites and from cyclin A-CDK2 autophosphoryla-
tion. Additional data file 6 is a figure showing the
autophosphorylation of cyclin A-CDK2 in vitro. Additional
data file 7 is a figure showing that cyclin B-CDK2 (F80A) and
cyclin E-CDK2 (F80A) complexes that may have formed in
the lysate represent a negligible fraction of the total amount
of CDK2 (F80A) activity. Additional data file 8 is a figure
showing the Northern analysis of RL12 expression.
Additional data file 1 Scheme of HEK293 cell lysate fractionation Scheme of HEK293 cell lysate fractionation. Click here for file Additional data file 2 Numbers of peptides identified in the lysate fractions Numbers of peptides identified in the lysate fractions. Click here for file Additional data file 3 Identified proline-directed phosphopeptide sequences, the corre- sponding protein names, and their functional categorizations Identified proline-directed phosphopeptide sequences, the corre- sponding protein names, and their functional categorizations. Click here for file Additional data file 4 Proteins and phosphopeptides identified for cyclin A-CDK2 and  cyclin B-CDK1 Proteins and phosphopeptides identified for cyclin A-CDK2 and  cyclin B-CDK1. Click here for file Additional data file 5 Phosphopeptides with non-proline-directed sites and from cyclin  A-CDK2 autophosphorylation Phosphopeptides with non-proline-directed sites and from cyclin  A-CDK2 autophosphorylation. Click here for file Additional data file 6 Autophosphorylation of cyclin A-CDK2 in vitro Autophosphorylation of cyclin A-CDK2 in vitro. Click here for file Additional data file 7 Cyclin B-CDK2 (F80A) and cyclin E-CDK2 (F80A) complexes that  may have formed in the lysate represent a negligible fraction of the  total amount of CDK2 (F80A) activity Cyclin B-CDK2 (F80A) and cyclin E-CDK2 (F80A) complexes that  may have formed in the lysate represent a negligible fraction of the  total amount of CDK2 (F80A) activity. Click here for file Additional data file 8 Northern analysis of RL12 expression Northern analysis of RL12 expression. Click here for file
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